Article info
PDFClinical trial
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial
- Correspondence to Dr Antonio Gonzalez Martin, Medical Oncology, Clinica Universidad de Navarra, Madrid 28027, Spain; agonzalezma{at}unav.es
Citation
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial
Publication history
- Accepted November 16, 2020
- First published December 14, 2020.
Article Versions
- Previous version (1 April 2021).
- Previous version (1 April 2021).
- You are currently viewing a Previous version of this article (1 April 2021).
- View the most recent version of this article
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.